0727 GMT - The market is pricing in tariff risks for pharma stocks despite drugs currently being exempt from U.S. President Trump's potential tariffs, Berenberg analysts say in a note. Uncertainty from tariffs and substantial layoffs at the Food and Drug Administration and other U.S. health departments have dragged pharma share prices lower, they say. Berenberg reiterate its buy ratings on U.K. drugmaker AstraZeneca and French pharma giant Sanofi due to share-price erosion and lower exposure to the U.S. market. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 08, 2025 03:27 ET (07:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.